Avatrombopag Global Buyers List: The Complete Guide to Sourcing, Distribution, and Market Access
Introduction: Why the Avatrombopag Buyers Landscape Matters
Avatrombopag has emerged as a cornerstone therapy in the treatment of thrombocytopenia, a condition characterized by abnormally low platelet counts. As a second-generation, orally administered thrombopoietin receptor agonist (TPO-RA), avatrombopag offers a convenient dosing profile and a favorable safety profile that has driven rapid adoption across global markets. Originally approved by the U.S. Food and Drug Administration in May 2018 for thrombocytopenia in adults with chronic liver disease undergoing procedures, avatrombopag has since expanded its indications to include chronic immune thrombocytopenia and pediatric ITP. As of May 2025, avatrombopag has been approved in 15 countries or regions, including Europe and the United States.
For pharmaceutical buyers, distributors, and procurement specialists, understanding the global avatrombopag buyers list is not merely a matter of identifying suppliers—it is about mapping a complex ecosystem of API manufacturers, finished-dose producers, specialty pharmacies, wholesalers, and public health tenders. This guide provides a comprehensive, actionable overview of that ecosystem, with verified data drawn from regulatory filings, trade records, and market intelligence.
What Is Avatrombopag? A Brief Clinical and Commercial Overview
Avatrombopag maleate is marketed under the brand name Doptelet by AkaRx Inc., a subsidiary of Swedish Orphan Biovitrum AB (Sobi). The drug works by mimicking the biological effects of thrombopoietin, stimulating the development and maturation of megakaryocytes, which in turn increases platelet production.
Commercially, avatrombopag is available as 20 mg film-coated tablets and, more recently, as an oral granule formulation (Doptelet Sprinkle) approved in the United States. The global market for avatrombopag maleate is projected to grow at a compound annual growth rate of approximately 6.8% during the forecast period, driven by expanding indications, increasing diagnosis rates for ITP and CLD-associated thrombocytopenia, and the convenience of oral administration compared to injectable alternatives.
Sobi holds full global commercial rights to Doptelet, with royalty obligations to Eisai Inc. and Astellas Inc. based on net sales. This centralized commercial structure has significant implications for buyers: while Sobi controls the branded product, generic and API sourcing operates through a separate, more fragmented supply chain.
The Global Avatrombopag Market at a Glance
The broader oral thrombopoietin receptor agonist market reached approximately USD 5.36 billion in global sales in 2025, with projections to reach USD 8.49 billion by 2032, representing a CAGR of 6.9%. Avatrombopag competes primarily with Novartis’ Promacta (eltrombopag) and Amgen’s Nplate (romiplostim), but its oral administration and lack of dietary restrictions give it a distinct commercial advantage.
Key regional markets for avatrombopag include:
- North America (United States, Canada, Mexico): The largest revenue-generating region, driven by FDA approvals and broad payer coverage.
- Europe (Germany, UK, France, Italy, Russia): Growing adoption following EMA authorization in June 2019.
- Asia-Pacific (China, Japan, South Korea, India, Australia): Rapidly expanding, with China emerging as a major consumption and manufacturing hub.
- Middle East and Africa: Nascent but growing, with procurement through public tenders and named-patient import pathways.
Avatrombopag Global Buyers List: Key Categories
The term “avatrombopag global buyers list” encompasses several distinct categories of purchasers. Understanding these categories is essential for suppliers and distributors seeking to target the right audience.
Finished-Dose Pharmaceutical Buyers and Importers
These are companies that purchase avatrombopag maleate tablets in finished form for distribution, repackaging, or clinical use.
API Buyers and Manufacturers
Avatrombopag maleate API is purchased by generic drug manufacturers, contract research organizations (CROs), and pharmaceutical companies developing bioequivalents or new formulations.
Verified API buyers and manufacturers include:
- Sinoway Industrial Co., Ltd. — Listed as a manufacturer and supplier of avatrombopag maleate API.
- Biophore India Pharmaceuticals Pvt Ltd — Holds active US DMF filings for avatrombopag.
- Granules India Limited — Active API manufacturer with avatrombopag filings.
- ChemWerth Inc — API supplier with avatrombopag DMF.
- Metrochem API Private Limited — Indian API manufacturer with avatrombopag filings.
- Nuray Chemicals Private Limited — API manufacturer with avatrombopag DMF.
- Honour Lab Limited — API manufacturer with avatrombopag filings.
- Reyoung Pharmaceutical — Chinese API manufacturer with active US DMF for avatrombopag.
- Sthree Chemicals Pvt. Ltd. — Indian API manufacturer offering avatrombopag maleate with US DMF.
As of recent regulatory filings, seven API manufacturers hold active US DMFs or CEPs for avatrombopag, with three shortage records across two countries.
Specialty Pharmacies and Distributors (United States)
In the United States, Doptelet prescriptions are filled exclusively through specialty pharmacies within the Doptelet network or by dispensing physician practices. Authorized specialty pharmacies and distributors include:
- Accredo — 888-608-9010
- Biologics by McKesson — 800-850-4306
- Kroger Specialty Pharmacy — 800-284-5071
- Dova 1Source — 1-833-368-2663
These distributors are authorized to dispense or distribute Doptelet and are critical nodes in the U.S. distribution chain.
Public Health Procurement and Tender Buyers
Governments and public health agencies represent a significant category of avatrombopag buyers, particularly in markets where the drug is not commercially distributed through traditional retail channels.
Named-Patient Import Buyers (Emerging Markets)
In countries where avatrombopag is not commercially registered—such as India and Egypt—buyers access the drug through named-patient import pathways. These pathways allow physicians to import the drug for individual patients under regulatory oversight. For avatrombopag specifically, the application is routine, involving an oral tablet with standard room-temperature handling and no REMS or controlled-substance complexity.
Key intermediaries in this segment include Reserve Meds, which coordinates U.S.-sourced Doptelet for named-patient import into India through a physician-led cross-border pathway.
Regulatory Landscape: What Buyers Need to Know
Avatrombopag’s regulatory footprint is expanding, which directly impacts the availability of buyers and suppliers in different regions.
United States (FDA)
Avatrombopag was approved by the FDA in May 2018 for CLD-associated thrombocytopenia and subsequently for chronic ITP. The FDA has also approved Doptelet for pediatric patients aged 1 year and older with persistent or chronic ITP. The reference listed drug is held by AkaRx Inc..
European Union (EMA)
Doptelet received EU marketing authorization on June 20, 2019, with Swedish Orphan Biovitrum AB (publ) as the marketing authorization holder. The EU authorization covers the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure and for primary chronic ITP in adults refractory to other treatments.
Japan (PMDA)
Avatrombopag was approved in Japan in March 2023 for the improvement of thrombocytopenia in patients with chronic liver disease scheduled for elective invasive procedures. The applicant is Swedish Orphan Biovitrum Japan Co., Ltd., and the product is marketed by Asahi Kasei Pharma. A partial change application for persistent and chronic ITP was approved in 2025.
China (NMPA)
China’s National Medical Products Administration approved avatrombopag maleate tablets for CLD-associated thrombocytopenia in June 2024. The product was initially launched in China on April 14, 2020, through a licensing agreement with Fosun Pharmaceutical, which holds exclusive sales rights in mainland China and Hong Kong. Generic manufacturers in China include Sichuan Kelun Pharmaceutical and Shanghai Xinyi Pharmaceutical.
South Korea (MFDS)
Handok has secured marketing approval from South Korea’s Ministry of Food and Drug Safety for Doptelet to treat chronic ITP and CLD-related thrombocytopenia.
Other Markets
Avatrombopag has also been approved in Australia, Russia, GCC countries, and Canada, with cumulative patient exposure estimated at over 30,000 patient-years across approved indications.
Key Manufacturers and Their Market Positions
The avatrombopag market features a mix of originator and generic manufacturers. The major global manufacturers of avatrombopag maleate tablets include:
In 2024, the world’s top three vendors accounted for a significant share of global revenue, underscoring the concentrated nature of the market at the finished-dose level.
How to Build a Targeted Avatrombopag Buyers List
For suppliers, API manufacturers, and distributors seeking to connect with avatrombopag buyers, a systematic approach is essential.
Step 1: Identify Your Target Segment
Determine whether you are targeting API buyers (generic manufacturers, CROs), finished-dose distributors (specialty pharmacies, wholesalers), or public health procurement agencies. Each segment has distinct purchasing behaviors, regulatory requirements, and decision-making processes.
Step 2: Leverage Trade Intelligence Platforms
Platforms such as 52wmb, PharmaOffer, Pharmacompass, and PharmaDB provide verified trade data, customs records, and supplier-buyer matching for avatrombopag. These platforms allow you to filter by region, certification (US DMF, CEP), and transaction history.
Step 3: Monitor Public Tenders
Government procurement portals in the EU, UK, and other regions regularly publish tenders for avatrombopag supply. The Malta Department of Contracts and Northern Ireland’s Health & Social Care Trust are examples of public buyers that have recently awarded avatrombopag contracts.
Step 4: Engage with Specialty Pharmacy Networks
In the United States, access to the avatrombopag market requires engagement with the Doptelet specialty pharmacy network. Building relationships with Accredo, Biologics by McKesson, and Kroger Specialty Pharmacy is essential for U.S. market penetration.
Step 5: Establish Regulatory Credentials
Buyers in regulated markets prioritize suppliers with active US DMFs, CEPs, or GMP certifications. Investing in regulatory filings and maintaining inspection-ready facilities is a prerequisite for accessing high-value buyers in the US, EU, and Japan.
Frequently Asked Questions (FAQ)
What is the difference between avatrombopag and avatrombopag maleate?
Avatrombopag maleate is the salt form of avatrombopag used in pharmaceutical formulations. The maleate salt improves stability and bioavailability. Both terms are often used interchangeably in commercial contexts.
Who are the largest buyers of avatrombopag API?
The largest buyers of avatrombopag API are generic drug manufacturers in India, China, and Bangladesh, including companies such as Atco Laboratories (Pakistan), Eisai Pharmaceuticals India, and various Chinese generic manufacturers listed in market research reports.
How can I verify a potential avatrombopag buyer?
Verify buyers through trade intelligence platforms (52wmb, PharmaOffer), regulatory databases (FDA DMF listings, EMA CEP database), and public procurement records. Cross-referencing multiple sources is recommended.
Is avatrombopag available through named-patient import?
Yes. In countries where avatrombopag is not commercially registered, physicians can import the drug through named-patient pathways. This is common in India, Egypt, and other emerging markets.
What are the key regulatory approvals for avatrombopag?
Avatrombopag is approved by the FDA (US), EMA (EU), PMDA (Japan), NMPA (China), MFDS (South Korea), and regulatory authorities in Australia, Russia, Canada, and GCC countries.
NOVICK BIO SCIENCES PRIVATE LIMITED
NOVITIUM LABS PRIVATE LIMITED
NUWILL RESEARCH AND INNOVATIONS PRIVATE LIMITED
AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED
ORBION PHARMACEUTICALS PRIVATE LIMITED
DRUG INTERNATIONAL LIMITED
DHL PAKISTAN PRIVATE LIMITED
JENPHAR BANGLADESH LIMITED CHANGED
VEEDA CLINICAL RESEARCH LIMITED
ADVITY RESEARCH PRIVATE LIMITED
AUROBINDO PHARMA LTD
EVEREST PHARMACEUTICALS LIMITED
KHADIJA AKIF
SULE MENE SAGLIK ARASTIRMA EGITIM DANISMANLIK BILISIM SANAYI TICARET ANONIM SIRKETI
AZIDUS LABORATORIES LIMITED
DR REDDY S LABORATORIES LTD
HETERO LABS LIMITED
SANDOZ PRIVATE LIMITED
SCITUS PHARMA SERVICES PRIVATE LIMITED
APOTEX RESEARCH PRIVATE LIMITED
BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED
BIOORGANICS AND APPLIED MATERIALS PRIVATE LIMITED
CLIANTHA RESEARCH LIMITED
SYNTHON CHILE LIMITADA
TORRENT PHARMACEUTICALS LTD
APPCURE LABS PRIVATE LIMITED
EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED
MSN LABORATORIES PRIVATE LIMITED
ORIENTAL FARMACEUTICA INDUSTRIAL COMERCIAL E INMOBILIARIA SO
SQUARE PHARMACEUTICALS PLC CHANGED
SYNGENE INTERNATIONAL LIMITED
XYLOPIA LABS PRIVATE LIMITED
ZISKA PHARMACEUTICALSLIMITED
AGP LIMITED
ALI MOHAMMAD SOOMRO
ATCO LABORATORIES LIMITED
ATCO LABORATORIES LTD
BANGLADESH LABWARE CORPORATION
BEACON PHARMACEUTICALS PLC
BETA DRUGS LIMITED
BIOFARMA ILAC SANAYI VE TICARET ANONIM SIRKETI
CAJAEXPRESS COURIER S A
CÔNG TY TRÁCH NHIỆM HỮU HẠN SINH DƯỢC PHẨM HERA
D AMICO SISTEMAS S A
DR REDDY S LABORATORIES LIMITED
DRUGLAND CORPORATION
ESHAA MAJEED
GENOME PHARMACEUTICAL PVT LTD
GENOME PHARMACEUTICALS PVT LIMITED
GENTRY CORPORATION LIMITED
HELIX PHARMA PRIVATE LIMITED
JINAY PHARMACEUTICALS PRIVATE LIMITED
KHAWAJA TRADERS KHADIJA AKIF
LINTA PHARMACEUTICALS PVT LIMITED
M S AGP LIMITED
M S HELIX PHARMA PVT LTD
M S LINTA PHARMACEUTICALS PVT LTD
M S SCILIFE PHARMA PVT LTD
MOLECULES ANALYTICAL LAB SOLUTIONS PRIVATE LIMITED
RECIPHARM PHARMASERVICES PRIVATE LIMITED
RENATA PLC CHANGED FROM RENATA
SCILIFE PHARMA PRIVATE LIMITED
STRIDES PHARMA SCIENCE LIMITED
TECHNO DRUGS LTD
TIANISH LABORATORIES PRIVATE LIMITED
TORRENT PHARMACEUTICALS LIMITED
WEATHER FOLDS PHARMACEUTICALS
WEATHERFOLDS PHARMACEUTICALS
ZENARA PHARMA PRIVATE LIMITED
Conclusion: Navigating the Avatrombopag Buyers Ecosystem
The global avatrombopag buyers list is not a static document—it is a dynamic network of pharmaceutical importers, API purchasers, specialty pharmacies, and public health agencies spanning every major region. For suppliers and distributors, success in this market requires a combination of regulatory readiness, trade intelligence, and targeted engagement with the right buyer segments.
As avatrombopag continues to expand its indications and geographic footprint, the buyers list will grow correspondingly. Companies that invest in understanding the regulatory landscape, building verified trade relationships, and monitoring procurement opportunities will be best positioned to capture value in this evolving market.
For the most current avatrombopag buyers list and trade intelligence, consult verified B2B pharmaceutical platforms and regulatory databases referenced throughout this guide.
